Sapiens · Weight · GLP-1

Ozempic Side Effects: What’s Common, What’s Serious

Q: How many people stop taking Ozempic because of side effects?

In trials, 4.3 percent of adults on the 2.4 mg dose stopped permanently because of a gastrointestinal reaction, versus 0.7 percent on placebo. Real-world discontinuation is far higher, around a third within twelve months, but that figure mixes cost, supply and satisfaction together with side effects.

Written by Dr. Tarun Reddy · Last reviewed: July 30th, 2026 · ~15 min read

A South Asian woman in a dimly lit kitchen at night, reading the label on a semaglutide injection pen beside an open refrigerator — Semaglutide (Ozempic) is a once-weekly injection kept in the fridge — most side effects are dose-related and ease over the first few weeks.

Atlas illustration of the body’s response to a GLP-1 medicine, drawn as a radial bloom of the gut, brain, muscle and eye territories.

In India, Ozempic is licensed for one thing — type 2 diabetes. Most people searching its side effects are asking because they’re taking it, or a cheaper generic semaglutide, to lose weight: an off-label use a doctor signs off on case by case.

That distinction runs through everything below, because the dose used for weight is higher than the diabetes dose, and side effects track the dose closely. Nearly everything people feel is digestive and settles. A shorter list — the pancreas, the gallbladder, dehydration, two different eye problems, one thyroid warning, and pregnancy — is where the real caution sits.

Quick facts

Ozempic is semaglutide — everything below applies to the generic brands now sold across India.
Nausea affected 15.8% at the 0.5 mg dose and 20.3% at 1 mg in diabetes trials, but 44% at the 2.4 mg weight-management dose.
Gut effects come from the medicine deliberately slowing digestion — the same action that curbs appetite.
Around 4% of people in trials stopped permanently because of them; real-world drop-off is far higher.
Two different eye risks get confused, and regulators and eye specialists don’t fully agree on what to do about one of them.
On its own it rarely causes low blood sugar — combined with a sulfonylurea or insulin, it can.
It must be stopped at least two months before a planned pregnancy.

What is Ozempic, and how does it work? Copy link

Ozempic is the brand name for semaglutide, a once-weekly injection from a class called GLP-1 receptor agonists. It copies a natural gut hormone and does three things: prompts the pancreas to release insulin when blood sugar is high, reduces the liver’s glucose output, and slows how fast the stomach empties while signalling fullness to the brain.¹ India’s CDSCO approved it for adults with type 2 diabetes in 2025, and Novo Nordisk launched it here that December.¹¹ The wider picture is in our guide to GLP-1 medications in India.

Why does Ozempic cause side effects? Copy link

Because slowing your stomach down is the mechanism. Food sits longer, you feel full on less, you eat less. Nausea, early fullness, bloating and constipation are that same slowdown, felt from the inside.

Nausea has a second source. Semaglutide also acts on the area postrema, the brainstem region that governs the sensation of feeling sick.¹ That’s why it peaks after starting and after each dose step-up — and why climbing the dose slowly is the single most effective thing that prevents it. The same mechanism across the whole drug class is covered in GLP-1 side effects.

What are the common side effects of Ozempic? Copy link

Digestive ones. In the pooled placebo-controlled trials behind the Ozempic label, five reactions occurred in at least 5% of people: nausea, vomiting, diarrhea, abdominal pain and constipation.¹

The dose relationship is more interesting than it first looks. Going from 0.5 mg to 1 mg, nausea rises (15.8% to 20.3%) and vomiting nearly doubles (5% to 9.2%). But diarrhea barely moves (8.5% to 8.8%), and abdominal pain and constipation both fall (7.3% to 5.7%, and 5% to 3.1%).¹ The overall gastrointestinal burden still climbs with dose — 32.7% of people at 0.5 mg and 36.4% at 1 mg reported some gut reaction, against 15.3% on placebo — but it’s driven by nausea and vomiting rather than by everything moving together.¹

At the 2.4 mg dose licensed elsewhere for weight management, the numbers are higher across the board: 44% reported nausea, with diarrhea 30%, vomiting 24% and constipation 24%, against placebo rates of 16%, 16%, 6% and 11%.⁶ That’s a different trial program in a different population, so it isn’t a controlled comparison — but if you’re using semaglutide off-label for weight, the higher figures are the ones that describe your situation.

Fig. 1 — Nausea rates by dose. These come from separate trial programs in different populations, so read them as a gradient, not a head-to-head test.

Reactions reported in at least 5% of people, from the Ozempic label’s placebo-controlled trials
Effect	Placebo	0.5 mg	1 mg	2.4 mg*
Nausea	6.1%	15.8%	20.3%	44%
Vomiting	2.3%	5.0%	9.2%	24%
Diarrhea	1.9%	8.5%	8.8%	30%
Abdominal pain	4.6%	7.3%	5.7%	20%
Constipation	1.5%	5.0%	3.1%	24%
Any gut reaction	15.3%	32.7%	36.4%	—

*The 2.4 mg column comes from a separate weight-management trial program in a different population, not from the same placebo-controlled pool. Below 5%, the label also lists dyspepsia, burping, flatulence, reflux and gastritis, plus fatigue, taste changes and dizziness.¹

Fig. 2 — One medicine, two sites of action: the stomach and the brainstem.

How long do Ozempic side effects last? Copy link

For most people the gut effects peak in the opening weeks and around each dose increase, then ease as the body adjusts. Severe gastrointestinal reactions are the exception rather than the rule: 0.4% at 0.5 mg and 0.8% at 1 mg, against none on placebo,¹ rising to 4.1% at the 2.4 mg weight dose versus 0.9% on placebo.⁶

Fig. 3 — A typical course. Individual timing varies; the dashed lines mark usual dose step-ups.

What starts when
Effect	Usually starts	Usually improves
Nausea	First days to weeks	Days to a few weeks; peaks after each step-up
Constipation	Early	Over weeks, with fluids and fiber
Loose motions	Early, variable	Usually settles over weeks
Reduced appetite	Early	Persists — this is intended
Fatigue	Early	Improves as intake steadies
Hair shedding	~2–4 months in	Reverses over months as weight stabilizes

Do side effects mean Ozempic is working? Copy link

No. How rough you feel measures how your particular body is adapting, not how much weight you’ll ultimately lose. Some people are quite nauseated early and lose a lot; others barely notice anything and respond just as well. If you’re sailing through the first weeks, that’s good news, not a sign the dose is too low. What the medicine typically delivers is set out in how much weight loss to expect on a GLP-1.

How many people stop because of side effects? Copy link

In trials, not many. On the diabetes doses, 3.1% at 0.5 mg and 3.8% at 1 mg stopped because of a gastrointestinal reaction, against 0.4% on placebo.¹ At the 2.4 mg weight dose it was 4.3%, against 0.7% on placebo.⁶

Real life is a different picture, and it’s worth knowing before you start. Observational studies have reported roughly a third of people stopping within twelve months of starting once-weekly semaglutide, and one analysis of injectable GLP-1 medicines found around 70% had discontinued within two years.¹² Those are observational figures that mix cost, supply, side effects and satisfaction together, so they can’t tell you why any individual stopped — but they do say that staying on treatment is the hard part, not starting it. What happens to weight afterwards is covered in stopping a GLP-1.

How do you manage the nausea? Copy link

The biggest lever isn’t a food or a supplement — it’s slow titration, raising the dose gradually so your body acclimatizes. That’s the main safety advantage of being supervised rather than self-dosing something bought online, and it’s covered in detail in how to start a GLP-1 safely.

Day to day: smaller portions, stopping at the first hint of fullness rather than finishing the plate out of habit, and going easy on greasy or very rich food that slows an already-slow stomach further. Bland, protein-containing meals — khichdi, dal, curd, soup, toast — tend to sit best; there’s a fuller list in what to eat on a GLP-1 in India. For constipation, fluids and fiber do most of the work. Where nausea is heavy early on, a doctor may add a short course of an anti-nausea medicine, and managing GLP-1 nausea goes further.

The one firm line: if you can’t keep fluids down, that isn’t something to tough out. Post-marketing reports of acute kidney injury on semaglutide have mostly occurred in people who became dehydrated through vomiting or diarrhea.¹

Can you drink alcohol on Ozempic? Copy link

There’s no absolute prohibition, and semaglutide doesn’t interact with alcohol the way some antibiotics do. The caution is practical and stacks in three layers. Alcohol irritates the stomach lining, which lands on top of nausea and reflux you may already have. It also drives fluid loss, which is the mechanism behind the dehydration problem above. And heavy drinking is an independent risk factor for pancreatitis, which is already on the watch list for this medicine.¹

If you also take a sulfonylurea or insulin, there’s a fourth: alcohol suppresses the liver’s glucose release and can produce delayed low blood sugar hours later, often overnight. Many people find their tolerance drops noticeably on treatment simply because they’re eating less. Sensible practice is modest amounts, not on an empty stomach, and not during the week you step the dose up.

Can Ozempic cause low blood sugar? Copy link

By itself, rarely. Semaglutide only pushes insulin out when blood sugar is already high, so used alone it doesn’t typically drive levels into hypoglycemia. The risk changes completely alongside a sulfonylurea — glimepiride, gliclazide, glibenclamide — or with insulin. Those lower sugar regardless of what your body needs, and adding semaglutide can push it too far.¹

Sulfonylureas are inexpensive and widely prescribed here, so they are often already in the pocket of someone who then starts semaglutide for weight. If that’s you, the sulfonylurea or insulin dose usually needs reducing when semaglutide starts — a prescribing decision, not something to adjust yourself. Know the signs: shakiness, sweating, a racing heart, sudden hunger, confusion, dizziness or blurred vision.

The two Ozempic eye risks, and why they get confused Copy link

Two genuinely different eye problems tend to get merged together. Separating them is the difference between sensible caution and unnecessary fear.

NAION — the optic-nerve one

In June 2025, Europe’s drug regulator concluded its review and added NAION — non-arteritic anterior ischemic optic neuropathy — to the product information for semaglutide medicines.³ It’s a sudden, usually painless loss of vision in one eye caused by reduced blood flow to the optic nerve.

The regulator put numbers on it rather than leaving it at “rare”. The frequency category is very rare: up to 1 in 10,000 people taking semaglutide. Epidemiological studies suggested roughly a two-fold increase in risk in adults with type 2 diabetes, which works out to about one additional case per 10,000 person-years of treatment — one person-year being one person taking it for one year.³ A 2026 study of 102,361 US veterans with type 2 diabetes found the same shape and put absolute numbers on it. Over a maximum 7.5 years of follow-up, NAION occurred at 123 per 100,000 person-years among semaglutide initiators against 67 per 100,000 among those starting an SGLT2 inhibitor. Expressed as cumulative risk over the study’s median 2.1 years of follow-up, that was 0.29% versus 0.13% — a roughly two-fold difference, on a small base.⁵

Then the regulators and the eye specialists diverge, and it’s worth knowing that they do. Europe’s position is that if NAION is confirmed, semaglutide should be stopped.³ The North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology, in a joint consensus statement, declined to endorse that as a blanket rule — their view is that stopping can itself carry significant risk for someone whose diabetes or obesity is otherwise hard to manage, and that the decision belongs to a conversation between the patient, their eye specialist and their prescriber.⁴ Both agree the overall magnitude is low and that causation isn’t established.

What’s not in dispute: sudden loss of vision or rapidly worsening eyesight means contact a doctor without delay, and tell them you’re on semaglutide.³

Diabetic retinopathy — the blood-sugar one

This is the risk far more relevant to Indian patients, and it isn’t really about the drug. In a two-year cardiovascular trial, complications of diabetic retinopathy occurred in 3.0% on semaglutide versus 1.8% on placebo. The label breaks that number down, and the breakdown is the whole story: among people with a history of retinopathy at baseline it was 8.2% versus 5.2%; among people without one, 0.7% versus 0.4%.¹

The explanation researchers settled on is that any rapid, large drop in HbA1c can transiently worsen existing retinal disease — an effect first described with intensive insulin therapy decades ago, not something unique to semaglutide.¹³ India’s own regulator has taken the same view in practice: CDSCO’s expert committee required that people with proliferative or unstable retinopathy be excluded from a semaglutide trial protocol.¹¹

The practical consequence is concrete. If you have type 2 diabetes — especially long-standing diabetes or any known retinopathy — get a dilated eye examination before starting, and stay on an ophthalmology follow-up schedule while your sugars fall. That converts this from a worry into a managed variable.

What about the thyroid warning? Copy link

Semaglutide carries a boxed warning — the strongest category of drug warning — because in rodents it caused thyroid C-cell tumors, including medullary thyroid carcinoma.¹ The warning is real, and its practical scope is narrow. Both halves matter.

The first: it is genuinely unknown whether this translates to humans, and human studies to date have not established that GLP-1 medicines cause medullary thyroid carcinoma.¹ The second: the warning still has a hard, practical edge. Semaglutide is contraindicated if you or a close family member have had medullary thyroid carcinoma, or if you have Multiple Endocrine Neoplasia syndrome type 2.¹ That’s a family-history question worth asking your relatives before you start, not after. A new lump or swelling in the neck, persistent hoarseness, or trouble swallowing should be reported. Other reasons not to start are in who should not take GLP-1 medicines.

Does Ozempic cause depression or suicidal thoughts? Copy link

The evidence available so far says no, and the question has been examined properly rather than dismissed. After case reports emerged in 2023, Europe’s safety committee reviewed around 150 reports of suicidal thoughts and thoughts of self-injury, together with non-clinical studies, clinical trial data, post-marketing surveillance, an analysis of electronic health records covering people with type 2 diabetes, and a separate study of over 240,000 people with overweight or obesity. In April 2024 it concluded that the available evidence does not support a causal association between GLP-1 medicines and suicidal or self-injurious thoughts and actions, and that no product-information change was warranted.¹⁰ The UK and US regulators reached the same conclusion independently.

Two honest caveats. “No causal association found” is not the same as “impossible”, and regulators have kept the question under routine monitoring. And separately from any drug effect, rapid weight change is a period when mood, body image and eating patterns can shift for ordinary reasons. If you have a history of depression or an eating disorder, that’s worth raising with the doctor supervising you at the start rather than after — not because the medicine is expected to cause a problem, but because it’s the sort of thing that’s much easier to manage when someone knows to look.

Pregnancy, contraception and other medicines Copy link

Semaglutide is prescribed off-label for weight to plenty of women of reproductive age, and the guidance here is time-sensitive — which makes it worth reading before you start rather than after.

Planning a pregnancy

Semaglutide should not be used in pregnancy: animal reproduction studies showed fetal harm, and human data remain insufficient.² Because the drug has a long half-life, the instruction is not simply “stop when you find out”. It should be discontinued at least two months before a planned pregnancy, so it has cleared before conception.²⁶ If a pregnancy happens unexpectedly while you’re on it, stop and contact your doctor. It’s also not recommended while breastfeeding.²

The corollary is that reliable contraception belongs in the conversation at the start of treatment, not as an afterthought. This is not because semaglutide makes the pill fail — pharmacokinetic studies found it did not meaningfully reduce levels of the hormones in combined oral contraceptives⁶ — but because of the fetal risk if a pregnancy occurs. There’s a further wrinkle worth naming: for women using semaglutide in the context of PCOS, weight loss can restore ovulation and fertility that had been absent, so pregnancy can become more likely at exactly the point people assume it isn’t. That overlap is covered in GLP-1 medicines and PCOS.

Your other tablets

Because semaglutide slows stomach emptying, it can change how quickly other oral medicines are absorbed. Formal interaction studies found no clinically relevant effect for most medications tested, so this is not a reason to panic about routine tablets.² Two specifics are worth carrying to your doctor:

Levothyroxine. Total thyroxine exposure increased by 33% when a single 600 mcg dose was given alongside oral semaglutide — the opposite direction to what most people assume, and consistent with slower stomach emptying allowing more complete absorption. Two caveats belong with that number: it comes from a 45-subject healthy-volunteer study of the oral tablet, not the injection, and it appears in the labels as a monitoring caution rather than a dosing rule.¹⁵ If you take thyroid medication, it’s a reason for your doctor to recheck thyroid function after you start, not to change the dose yourself.
Warfarin and other narrow-margin medicines. Semaglutide didn’t change the overall effect of warfarin, but more frequent INR monitoring is advised when treatment starts.² The same principle applies to any medicine where a small change in level matters.

How should you store Ozempic? Copy link

Semaglutide is a peptide, and heat degrades peptides. An unopened pen belongs in the refrigerator at 2–8°C. Once you’ve used it, you can keep it refrigerated or at room temperature for up to 56 days, after which the pen is discarded even if medicine remains.¹

The catch is the definition of room temperature: the ceiling is 30°C. Across much of India for much of the year, an unairconditioned room sits above that, which quietly makes the refrigerator the only compliant option here for most of the year — not the convenience it is in temperate countries. Two more rules: never freeze it, and discard a pen that has frozen, because freezing destroys the molecule and the pen will look perfectly normal. Degraded semaglutide doesn’t announce itself — it just works less well, which is easy to misread as the medicine failing.

This is also the practical argument for buying through a pharmacy with a functioning cold chain rather than the cheapest online listing. The medicine is only as good as the temperature history you can’t see.

Are generic semaglutide side effects different? Copy link

Same molecule, same side-effect profile. Since semaglutide’s India patent expired in March 2026, more than forty generic brands have arrived — vials from around ₹1,290 a month, pre-filled pens from roughly ₹1,800.⁹ Details are in our guide to generic semaglutide in India.

What changes isn’t the chemistry, it’s the practicalities. A vial means drawing your own dose with a syringe, which leaves more room for error than a pen. And buying online without supervision removes the slow titration that prevents most of the bad early nausea — along with the person who would have checked your sulfonylurea dose, your eyes, and whether you might become pregnant. India’s CDSCO reaffirmed in 2026 that these are prescription-only medicines and moved against illegal sale and misleading promotion.⁹

Does Ozempic cause muscle loss or hair shedding? Copy link

Both happen, both are manageable, and both turn on what you eat while the weight is coming off.

Muscle loss

When weight comes off fast, some of it is muscle. The best data come from the body-composition substudy of the STEP 1 trial, and they cut both ways. Total lean mass fell 9.7% over 68 weeks, and depending on how it’s calculated, lean tissue accounted for roughly 39–45% of the total weight lost — a large share, and higher than several other agents.⁷ But the same substudy found that lean mass as a proportion of total body mass rose by 3 percentage points, and the lean-to-fat ratio improved from 1.34 to 1.57.⁷ In other words: you lose real muscle, and your body composition still improves on average. The second finding doesn’t cancel the first.

The first half is worth taking seriously because many South Asians start from a lower muscle base. Yajnik’s Pune Maternal Nutrition Study described the “thin-fat” Indian phenotype — newborns thin in lean mass but preserving body fat — and the pattern persists into adulthood, where Indians carry more body fat and less skeletal muscle than Europeans at the same BMI.⁸ Starting with less muscle means losing the same proportion costs you more.

The protein arithmetic is where this bites. ICMR-NIN’s 2020 recommendations set the adult protein RDA at 0.83 g/kg/day, with an explicit footnote that people eating cereal-based diets with lower-quality protein need about 1 g/kg/day.¹⁴ That is the floor for preventing deficiency in a weight-stable adult — not a target for protecting muscle during rapid weight loss, which the wider obesity-medicine literature places higher still, commonly in the region of 1.2–1.6 g/kg paired with resistance training. Hitting even the ICMR floor is hard once appetite drops on a plate built around rice, roti and snacks, and harder on a vegetarian one. This is a conversation to have with a doctor or dietitian who can do the sums against your actual weight.

Hair shedding

Increased hair fall appearing around two to four months in is usually telogen effluvium — a temporary shed triggered by the stress of rapid weight loss and reduced intake, not the drug damaging follicles. It typically reverses as weight and nutrition stabilize. Making sure ferritin, thyroid and vitamin D aren’t low stops an underlying deficiency from compounding it.

The rare but serious side effects Copy link

A small number of presentations mean stop and get assessed rather than wait. These are uncommon — gallstones, for instance, were reported by 1.6% of people at the 2.4 mg dose⁶ — but they’re the ones worth knowing by name.

Fig. 4 — The signs that warrant urgent review rather than waiting.

Warning signs and what they may point to
Warning sign	What it may point to
Severe, persistent upper-abdominal pain boring through to the back, often with vomiting	Pancreatitis — stop and seek care
Sharp right-upper-abdominal pain, fever, or yellowing of the eyes or skin	Gallbladder problem (gallstones)
Ongoing vomiting or diarrhea with dizziness and very little urine	Dehydration, possible acute kidney injury
Sudden loss or change of vision in one eye	Possible NAION — urgent eye assessment
New neck lump or swelling, persistent hoarseness, trouble swallowing	Thyroid — needs assessment
Severe, persistent vomiting with fullness long after eating	Marked delayed stomach emptying (gastroparesis)
Rash, swelling of face or throat, difficulty breathing	Allergic reaction — emergency

Rapid weight loss by itself raises gallstone risk, which is one more reason steady, supervised loss beats the fastest possible drop.

Before any surgery, endoscopy or procedure with sedation, tell the team you’re on semaglutide. Because the drug slows stomach emptying, food can remain in the stomach longer than standard fasting rules assume, raising the risk of it entering the lungs under anesthesia. Regulators note there isn’t yet enough evidence to say whether changing fasting times or pausing the drug reduces that risk — which is precisely why the anesthetist needs to know rather than guess.¹

Which tests are worth doing alongside Copy link

Most of what makes side effects manageable is decided before the first dose. A baseline set — kidney and liver function, HbA1c, thyroid, ferritin and vitamin D — gives your doctor a reference point, catches the deficiencies that make fatigue and shedding worse, and gives something to compare against later. Add a dilated eye check if you have diabetes, a review of every other medicine you take, and a pregnancy plan if that applies. The full list is in GLP-1 blood tests.

When to see a doctor Copy link

Go without waiting for any of the warning signs above, and for nausea or vomiting you can’t drink through. Also worth a conversation: side effects that aren’t settling after a few weeks at a steady dose, repeated low-sugar episodes if you’re also on a sulfonylurea or insulin, hair shedding continuing past six months, losing weight much faster than expected, or any plan to try for a pregnancy in the next six months. The aim was never to grit your teeth through severe symptoms — it’s to find the lowest dose that works well for you.

Frequently asked questions Copy link

What are the most common side effects of Ozempic?

Digestive ones: nausea, vomiting, diarrhea, abdominal pain and constipation. Nausea affected 15.8% at 0.5 mg and 20.3% at 1 mg in the diabetes trials, and 44% at the 2.4 mg weight-management dose. They don’t all rise together, though — between 0.5 mg and 1 mg nausea and vomiting increase while abdominal pain and constipation fall.

How long do Ozempic side effects last?

For most people, days to a few weeks, peaking after each dose step-up and settling as the body adjusts. Raising the dose slowly is the best way to limit them.

Does Ozempic cause eye problems?

Two separate issues. NAION, an optic-nerve condition, was added to semaglutide’s product information in 2025 as very rare — up to 1 in 10,000, roughly one extra case per 10,000 person-years. Separately, in people who already have diabetic retinopathy, a rapid fall in blood sugar can temporarily worsen it.

Should you stop Ozempic if you get NAION?

European regulators say semaglutide should be stopped if NAION is confirmed. The North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology declined to endorse that as a blanket rule, recommending shared decision-making instead, because stopping can carry its own risks. Either way, sudden vision change in one eye needs urgent assessment.

Can Ozempic cause low blood sugar?

On its own, rarely, because it only stimulates insulin when sugar is high. The risk rises sharply alongside a sulfonylurea such as glimepiride, or insulin — both common in India. Those doses often need reducing when semaglutide starts.

Do you need to stop Ozempic before pregnancy?

Yes. Because of the long half-life, semaglutide should be discontinued at least two months before a planned pregnancy, and it isn’t used during pregnancy or breastfeeding. If a pregnancy occurs unexpectedly, stop and contact your doctor.

Does Ozempic cause depression or suicidal thoughts?

Europe’s safety committee reviewed around 150 reports plus trial and health-record data and concluded in April 2024 that the evidence does not support a causal association. UK and US regulators agreed. Rapid weight change can still affect mood for other reasons, so a history of depression is worth flagging at the start.

Does Ozempic cause thyroid cancer?

It caused thyroid C-cell tumors in rodents, which is why it carries a boxed warning, but no human study has established it causes medullary thyroid carcinoma. It’s contraindicated if you or a close relative have had medullary thyroid carcinoma, or if you have MEN 2.

Does Ozempic cause muscle loss?

In the STEP 1 body-composition substudy, lean mass made up roughly 39–45% of the weight lost. But lean mass as a proportion of total body mass rose 3 percentage points and the lean-to-fat ratio improved, so composition got better overall. Protein and resistance training are what protect the muscle.

How many people stop taking Ozempic because of side effects?

In trials, 4.3% of adults on the 2.4 mg dose stopped permanently because of a gastrointestinal reaction, versus 0.7% on placebo. Real-world discontinuation is far higher — roughly a third within a year — but that mixes cost, supply and satisfaction with side effects.

Can you drink alcohol on Ozempic?

There’s no absolute ban, but alcohol irritates the stomach, worsens dehydration, and heavy drinking independently raises pancreatitis risk. If you also take a sulfonylurea or insulin it can cause delayed low blood sugar. Modest amounts, with food, and not during a dose increase.

Does Ozempic need to be refrigerated in India?

Unopened pens need 2–8°C. After first use a pen can be kept at room temperature for up to 56 days, but only below 30°C — which much of India exceeds indoors for much of the year, so the fridge is usually the only reliable option. Never freeze it.

Are generic semaglutide side effects the same as Ozempic?

Yes — same molecule, same profile. The practical differences are vials you draw yourself and buying without supervision, which removes the slow titration that prevents most early nausea.

Is Ozempic approved for weight loss in India?

In India it’s approved for type 2 diabetes, not as a stand-alone weight-loss medicine. Use for weight is off-label and should only happen under a doctor’s evaluation. See Ozempic in India for the full picture.

References Copy link

Ozempic (semaglutide) injection — full prescribing information. US Food and Drug Administration. Boxed warning on thyroid C-cell tumours and MTC/MEN 2 contraindication; nausea 15.8% (0.5 mg) and 20.3% (1 mg); diabetic retinopathy complications 3.0% vs 1.8% placebo, stratified 8.2% vs 5.2% with prior retinopathy and 0.7% vs 0.4% without; hypoglycaemia with insulin secretagogues; pancreatitis, acute kidney injury and anaesthesia guidance; storage. accessdata.fda.gov — Ozempic prescribing information
Ozempic (semaglutide) — EU Summary of Product Characteristics, European Medicines Agency. Discontinue at least 2 months before a planned pregnancy due to the long half-life; not for use in pregnancy or breastfeeding; delayed gastric emptying and oral drug absorption; INR monitoring on initiation with warfarin. ema.europa.eu — Ozempic EPAR
PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. European Medicines Agency, 6 June 2025. Frequency ‘very rare’ (up to 1 in 10,000); approximately two-fold risk increase corresponding to roughly one additional case per 10,000 person-years; treatment should be stopped if NAION is confirmed. ema.europa.eu — PRAC NAION conclusion
Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by NANOS and the American Academy of Ophthalmology. Evidence is primarily retrospective observational; overall magnitude of risk remains low; shared decision-making rather than a blanket rule on stopping. aao.org — NANOS/AAO consensus statement
Heberer K, Bress AP, Cogill S, et al. New-onset nonarteritic anterior ischemic optic neuropathy and initiators of semaglutide in US veterans with type 2 diabetes. JAMA Ophthalmol. 2026;144(3):259–264. doi:10.1001/jamaophthalmol.2025.6262 (published online 12 February 2026). Target-trial emulation in a nationwide VA cohort: 11,478 semaglutide initiators versus 90,883 SGLT2-inhibitor initiators, 102,361 total; NAION 123 vs 67 per 100,000 person-years; absolute risk low. Observational, active-comparator design. JAMA Ophthalmol. 2026;144(3):259–264
Wegovy (semaglutide) injection — full prescribing information. US Food and Drug Administration. Adverse-reaction table at the 2.4 mg dose: nausea 44%, diarrhoea 30%, vomiting 24%, constipation 24% versus placebo 16%, 16%, 6%, 11%; severe GI reactions 4.1% vs 0.9%; permanent discontinuation for GI reasons 4.3% vs 0.7%; cholelithiasis 1.6%; oral contraceptive exposure unaffected; discontinue at least 2 months before a planned pregnancy. accessdata.fda.gov — Wegovy prescribing information
Wilding JPH, Batterham RL, Calanna S, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc. 2021;5(Suppl 1):A16–A17. doi:10.1210/jendso/bvab048.030 (PMCID: PMC8089287). DEXA substudy: total lean body mass −9.7%, total fat mass −19.3%, visceral fat −27.4%; lean mass as a proportion of total body mass increased 3.0 percentage points; lean:fat ratio 1.34 → 1.57. Note: this is a conference abstract supplement reporting an exploratory analysis of a substudy, not powered for these endpoints — the weakest evidence grade cited on this page. J Endocr Soc. 2021;5(Suppl 1):A16–A17
Yajnik CS, Fall CHD, Coyaji KJ, et al. Neonatal anthropometry: the thin–fat Indian baby. The Pune Maternal Nutrition Study. International Journal of Obesity, 2003;27:173–180. Indian newborns are thin in lean mass while preserving body fat; the pattern persists into adulthood, with higher body fat and lower skeletal muscle than Europeans at equivalent BMI. Int J Obes. 2003 — Pune Maternal Nutrition Study
Semaglutide patent expiry in India (20 March 2026) and 40+ generic launches with vial and pen pricing; CDSCO enforcement on prescription-only status and misleading promotion. FiercePharma, 2026. Trade reporting, cited for market and pricing facts only. fiercepharma.com
GLP-1 receptor agonists: available evidence not supporting link with suicidal and self-injurious thoughts and actions. PRAC meeting highlights, European Medicines Agency, 8–11 April 2024. Review of ~150 case reports plus non-clinical studies, clinical trials, post-marketing surveillance and two electronic-health-record studies; no product-information update warranted. ema.europa.eu — PRAC April 2024
Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), Central Drugs Standard Control Organisation, Government of India — semaglutide injection 0.25/0.5/1 mg, M/s Novo Nordisk India; includes the requirement to exclude subjects with proliferative or unstable retinopathy and maculopathy. See also the CDSCO register of approved new drugs. cdsco.gov.in — SEC recommendations
Patient perceptions and real-world persistence with semaglutide: SUSTAIN-6 premature discontinuation 22.6% over 24 months; observational reports of ~33% discontinuation at 12 months after starting once-weekly semaglutide and up to 70.1% within 24 months across injectable GLP-1 agonists. Observational data — conflates cost, supply, tolerability and satisfaction. PMC — real-world discontinuation
Vilsbøll T, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes, Obesity and Metabolism, 2018. Post-hoc analysis of SUSTAIN 6: early worsening of retinopathy tracks the magnitude and rapidity of HbA1c reduction and pre-existing retinopathy, consistent with the long-recognised effect seen with intensive insulin therapy. Diabetes Obes Metab. 2018
Nutrient Requirements for Indians — Recommended Dietary Allowances and Estimated Average Requirements, 2020. ICMR–National Institute of Nutrition. Adult protein RDA 0.83 g/kg/day (EAR 0.66 g/kg/day), with the footnote that people consuming cereal-based diets with lower-quality protein require approximately 1 g/kg/day. nin.res.in — ICMR-NIN 2020
Rybelsus (oral semaglutide) prescribing information, US Food and Drug Administration — total thyroxine AUC increased 33% (90% CI 1.25–1.42) after a single 600 mcg levothyroxine dose given with oral semaglutide at steady state; Cmax unchanged. Source study: Hauge C, Breitschaft A, Hartoft-Nielsen ML, Jensen S, Bækdal TA. Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial. Expert Opin Drug Metab Toxicol. 2021;17(9):1139–1148. doi:10.1080/17425255.2021.1955856 (n=45). The finding is from the oral tablet, not the injection; both labels carry it as a monitoring caution for narrow-therapeutic-index oral medicines. FDA Rybelsus PI; Hauge et al. 2021, n=45

This article is for general education and is not a substitute for personal medical advice. Semaglutide is a prescription-only medicine; in India it is approved for type 2 diabetes, and use for weight management is off-label and requires a doctor’s evaluation. Never start, stop or change a dose on your own, and never adjust a diabetes medicine yourself. Written by Dr Tarun Reddy, MBBS.